Solos Endoscopy, Inc.'s (PINK:SNDY) reached up 45.95% in morning trading to $.0054 with 21M shares traded. Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Solos Endoscopy, Inc.'s (SNDY) announced that the Company has begun marketing its new endoscopic instrument line, SteriTAP™. Solos' SteriTAP™ Instruments are designed to be the ultimate sterile "take a part" endoscopic instruments of their kind and will be marketed and sold worldwide by Solos Endoscopy.
Preventia Inc. (OTCBB:PVTA) reached up 27.91% in morning trading to $.55 with 900K shares traded. Preventia Inc., a company incorporated pursuant to the laws of the State of Nevada is headquartered in Toronto, Ontario, Canada. The Company works with corporate clients through its subsidiary, Preventia Group Corp., to develop, market and distribute financial products for dematerialization and electronic trading and offers a patented electronic trading platform with respect to the foregoing. Preventia Group Corp., a subsidiary of Preventia Inc. (PVTA), has entered into a 5-year Services Agreement with Private Trading Systems PLC’s operational subsidiary, Private Trading Systems Corp. “PTS Panama”.
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) reached up 15.40% in morning trading to $.9001 with 1M shares traded. Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system, including addiction and epilepsy. Catalyst has two products in development, CPP-109 and CPP-115. It is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109, for the treatment of cocaine addiction. Both CPP-109 and CPP-115 have been granted "Fast Track" status by the FDA for the treatment of cocaine addiction. Catalyst is also planning to evaluate CPP-109 for the treatment of other addictions. Catalyst Pharmaceutical Partners, Inc. (CPRX) yesterday announced that it expects to report top-line results from its CPP-109 (vigabatrin) Phase II(b) trial around the end of September 2012 versus the previous guidance of early in the first quarter of 2013.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
